Myriad Asks Fed. Circ. To Block Ambry Cancer Test In IP Row


William Gaede and Eric Hagen continue to represent a life sciences leader in patent litigation brought by a competitor over cancer-testing products. In the latest developments, the competitor has asked the Federal Circuit to overrule a district court’s finding that its patents were likely invalid for claiming patent-ineligible subject matter.